Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer
Status:
Withdrawn
Trial end date:
2018-08-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether molecularly tailored therapy can improve
the efficacy of treatment when compared to standard chemotherapy combinations for patients
with metastatic pancreatic cancer receiving their second line of therapy for metastatic
disease.
Phase:
Phase 2
Details
Lead Sponsor:
Georgetown University
Collaborators:
Caris Life Sciences, Inc Cedars-Sinai Medical Center Companion Diagnostics, Inc. George Mason University Guardant Health, Inc. Sinai Health System Theranostics Health, Inc Thomas Jefferson University Virginia Mason Hospital/Medical Center